-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read for reference.
Well tolerated and effective in lowering blood pressure.
You should know the combination of Olmesartan Medoxomil + Amlodipine.
Olmesartan medoxomil is the latest generation of angiotensin II receptor antagonist.
The structural features of its 2 side chains and 4 AT1 receptor binding sites enable it to have a strong and stable antihypertensive ability.
Amlodipine is a classic and commonly used dihydropyridine calcium channel blocker (CCB), which can effectively dilate peripheral arterioles and reduce afterload, thereby reducing blood pressure and reducing myocardial oxygen consumption.
A previous clinical study named AZTEC showed that the compatibility of amlodipine + olmesartan medoxomil can effectively lower blood pressure and ensure stable blood pressure in patients with hypertension within 24 hours.
But it should be noted that patients with hypertension often have comorbidities.
Diabetes is a common chronic disease.
For patients with comorbid hypertension and diabetes, can the compatibility of amlodipine + olmesartan medoxomil still benefit them? Take a look at this study together To clarify this issue, a phase IV, open-label, multi-center clinical study enrolled 207 patients with high blood pressure between the ages of 19 and 80 with co-diabetics.
The study lasted 22 weeks.
Exclusion criteria include: refractory hypertension, diabetes patients who need insulin injection, glycosylated hemoglobin>9%, proteinuria 1+, serum creatinine>1.
7mg/dl or fasting blood glucose>300mg/dl.
Non-conventional arm circumferences <24cm or >42cm were considered to be associated with serious diseases and were therefore excluded.
Considering pregnancy and lactation restrictions, only strict contraception or women of non-reproductive age can participate in this study.
After 2-3 weeks of placebo introduction period, the subjects received amlodipine 5 mg, amlodipine/olmesartan medoxomil 5/20 mg, 5/40 mg, and 10/40 mg in the order of each regimen for 3 weeks.
After the intervention for 12 weeks, the subjects' sitting blood pressure was measured.
If the subject's systolic blood pressure was ≥130mmHg at this time, then continue to follow amlodipine/olmesartan medoxomil 10/40mg + hydrochlorothiazide 12.
5mg, amlodipine/olmesartan medoxomil 10/ 40 mg + 25 mg hydrochlorothiazide were administered sequentially for each regimen for 3 weeks for intervention.
Table: Summary of characteristics of subjects at baseline Figure 1: Study design (ABPM: ambulatory blood pressure monitoring; AML: amlodipine) The primary end point of the study is the change in arterial blood pressure after 12 weeks of treatment compared to baseline at 24 hours.
Simultaneous study The safety of drug use was also evaluated.
Figure 2: A.
Comparison of baseline and 12-week average 24-hour dynamic blood systolic blood pressure per hour; B.
Baseline and 12-week average 24-hour dynamic blood diastolic blood pressure comparison between baseline and sitting blood pressure of 158.
8±13.
1/89.
1±10.
1mmHg , The average 24-hour ambulatory blood pressure is 144.
4±11.
7/81.
6±9.
8mmHg.
After 12 weeks of intervention, the average 24-hour ambulatory blood pressure of the population decreased by -19.
9±0.
8/-11.
2±0.
5mmHg (p <0.
0001), and the 24-hour ambulatory blood pressure of 70% of patients reached the standard (<130/80mmHg).
In addition, for subjects whose blood pressure was not up to standard at 12 weeks and hydrochlorothiazide treatment, the average 24-hour ambulatory blood pressure drop after 18 weeks of treatment decreased by 28.
0±1.
5/13.
7±1.
0 mmHg (p <0.
0001) compared with baseline.
Among them, 62% of patients reached the recommended sitting blood pressure target (<130/80mmHg).
In terms of safety, 19.
3% of patients had adverse reactions caused by drugs.
The most common adverse events were peripheral edema, dizziness and hypotension.
In the superimposed hydrochlorothiazide group, the incidence of dizziness and hypotension was slightly higher than that in the non-combined application group, but no metabolic-related side effects caused by the drug were seen.
This study shows that the antihypertensive regimen of amlodipine + olmesartan medoxomil with or without hydrochlorothiazide is well tolerated for patients with type 2 diabetes and hypertension, and can achieve stable blood pressure control within 24 hours and reduce early morning hypertension.
Potential cardiovascular risk.
In 2005, the American Heart Association believed that the normal 24-hour blood pressure, day blood pressure and night blood pressure should be <130/80mmHg, <135/85mmHg and 120/70mmHg.
In this trial, 70% of subjects can be treated with amlodipine + olmesartan medoxomil to control the 24-hour blood pressure at <130/80mmHg.
TIME interactive time is convenient to use and has few side effects.
Olmesartan medoxomil and amlodipine are suitable for hypertensive patients of all ages.
Lin Wei, deputy chief physician of the Department of Cardiology, Beijing Boai Hospital.
Can not be fixed.
Therefore, for young hypertensive patients who have used single-agent blood pressure control that does not meet the standard, the single-tablet compound preparation olmesartan medoxomil and amlodipine can control blood pressure more effectively and stably.
Single-tablet compound preparations are simple to use.
Only one tablet a day is needed to keep the patient's blood pressure up to standard and improve the prognosis of hypertension.
In addition, the elderly are likely to have orthostatic hypotension and high blood pressure fluctuations.
I will also give priority to it.
Olmesartan medoxomil and amlodipine help blood pressure reach the target, improve the damage of target organs of hypertension, the incidence of hypotension is low, and it has significant advantages in clinical application.
Clinical experience shows that olmesartan medoxomil and amlodipine have better antihypertensive effects than other types of compound preparations Chen Wei, chief physician of the Department of Cardiology, Qingdao Central Hospital, 2020 European Society of Hypertension/European Society of Cardiology (ESH/ESC) Hypertension Management Guidelines clearly point out : Most hypertensive patients should start to use combination therapy to increase the rate of compliance.
Angiotensin receptor antagonist (ARB)/CCB combination, especially single-tablet compound preparation, is the preferred initial combination therapy for most hypertensive patients.
ARB olmesartan medoxomil, as the latest generation of ARB drugs, has a more potent, long-lasting and stable antihypertensive effect due to its unique "2046" structure.
Its combination with CCB amlodipine is a powerful antihypertensive treatment The model of strong combination is a clinically preferred treatment plan that can achieve strong blood pressure reduction, high compliance rate and good tolerability.
Olmesartan and amlodipine reduce the incidence of peripheral edema and improve patient compliance, especially in reducing central arterial pressure, which is significantly better than other combinations.
It is the preferred solution for patients with hypertension.
As one of the first national hypertension standard centers, our department has accumulated considerable experience in the use of olmesartan medoxomil and amlodipine tablets.
For patients whose single drug does not meet the standard, or the combination of two or more single drugs does not meet the standard, or the use of other compound preparations still does not meet the standard, it is recommended to use olmesartan medoxomil and amlodipine tablets, which have achieved ideal blood pressure lowering effects.
It is especially suitable for the elderly who take more drugs in combination.
ARB has been applied but the effect of lowering blood pressure is not good, consider switching to Olmesartan medoxomil Liang Yuqing, Deputy Chief Physician of Department of Cardiology, Beijing Chuiyangliu Hospital, Olmesartan Amlodipine Tablets have proven their potent antihypertensive effect, whether it is simple or high Blood pressure patients, or special populations (such as hypertension patients with diabetes, hypertension patients with obesity, elderly hypertension patients, etc.
) Olmesartan medoxomil and amlodipine have good blood pressure lowering effects, and its blood pressure reduction range can be based on the patient's blood pressure Changes in the baseline level can better reduce the occurrence of adverse reactions.
In clinical work, for patients who have already used ARB but still have poor blood pressure control, I will choose to switch to olmesartan medoxomil and amlodipine to help patients achieve their target blood pressure.
Clinical application experience sharing Teng Jiwei, deputy chief physician of the Department of Cardiology, the Second Affiliated Hospital of the PLA Air Force Military Medical University, reduces blood pressure all day long, and olmesartan medoxomil and amlodipine improve patient compliance.
The compound combination preparation for the treatment of hypertension has been increasing.
The more such drugs can reduce the frequency of medication and help improve patient compliance with medication.
Olmesartan medoxomil and amlodipine can reduce blood pressure throughout the day for a long time.
The incidence of adverse events is as low as 2%, and the occurrence of edema is significantly lower than that of amlodipine alone.
Therefore, the application of the drug can significantly improve the quality of life of patients and improve patient compliance.
For patients with acute coronary syndrome and heart failure, the application of ARB can improve the patient's ventricular remodeling and improve the patient's heart function.
Dai Jinjie, Deputy Chief Physician of the Department of Cardiology, Shanghai Jiao Tong University Chest Hospital, is mature in single-drug applications, and combined with more significant effects.
Combining drugs is a trend in the treatment of hypertension.
ARB and CCB are both mature drug types that have accumulated many years of experience in drug use.
The combination of serotonin helps to reduce blood pressure and reduce the occurrence of side effects.
Olmesartan medoxomil and amlodipine can make 85% of Chinese hypertensive patients reach the standard without increasing the incidence of hypotension.
The patients have good tolerance and compliance, so the antihypertensive effect is worth looking forward to.
Wang Yunman, Deputy Chief Physician of the Department of Nephrology, Shanghai Putuo District Central Hospital, blood pressure reduction + kidney protection should be the dual standard of antihypertensive medication for patients with CKD.
For CKD patients, the survival benefit of pure blood pressure control is dependent on the patient’s nephropathy.
Progress and weakening.
Taking urinary protein as the treatment target can effectively inhibit the progression of kidney disease and protect renal function.
ARB can reduce blood pressure while reducing urinary protein to protect kidney function.
Olmesartan medoxomil and amlodipine have sufficient evidence-based medical support, which is in line with the latest European guidelines for hypertension and the Chinese guidelines for single-tablet compound preparation recommendations.
We believe that blood pressure control and renal function protection require the combination of ARB and CCB.
Their strong combination can truly increase the rate of patient blood pressure compliance and improve patient compliance.
Scan the QR code below to get more cardiovascular knowledge.
Well tolerated and effective in lowering blood pressure.
You should know the combination of Olmesartan Medoxomil + Amlodipine.
Olmesartan medoxomil is the latest generation of angiotensin II receptor antagonist.
The structural features of its 2 side chains and 4 AT1 receptor binding sites enable it to have a strong and stable antihypertensive ability.
Amlodipine is a classic and commonly used dihydropyridine calcium channel blocker (CCB), which can effectively dilate peripheral arterioles and reduce afterload, thereby reducing blood pressure and reducing myocardial oxygen consumption.
A previous clinical study named AZTEC showed that the compatibility of amlodipine + olmesartan medoxomil can effectively lower blood pressure and ensure stable blood pressure in patients with hypertension within 24 hours.
But it should be noted that patients with hypertension often have comorbidities.
Diabetes is a common chronic disease.
For patients with comorbid hypertension and diabetes, can the compatibility of amlodipine + olmesartan medoxomil still benefit them? Take a look at this study together To clarify this issue, a phase IV, open-label, multi-center clinical study enrolled 207 patients with high blood pressure between the ages of 19 and 80 with co-diabetics.
The study lasted 22 weeks.
Exclusion criteria include: refractory hypertension, diabetes patients who need insulin injection, glycosylated hemoglobin>9%, proteinuria 1+, serum creatinine>1.
7mg/dl or fasting blood glucose>300mg/dl.
Non-conventional arm circumferences <24cm or >42cm were considered to be associated with serious diseases and were therefore excluded.
Considering pregnancy and lactation restrictions, only strict contraception or women of non-reproductive age can participate in this study.
After 2-3 weeks of placebo introduction period, the subjects received amlodipine 5 mg, amlodipine/olmesartan medoxomil 5/20 mg, 5/40 mg, and 10/40 mg in the order of each regimen for 3 weeks.
After the intervention for 12 weeks, the subjects' sitting blood pressure was measured.
If the subject's systolic blood pressure was ≥130mmHg at this time, then continue to follow amlodipine/olmesartan medoxomil 10/40mg + hydrochlorothiazide 12.
5mg, amlodipine/olmesartan medoxomil 10/ 40 mg + 25 mg hydrochlorothiazide were administered sequentially for each regimen for 3 weeks for intervention.
Table: Summary of characteristics of subjects at baseline Figure 1: Study design (ABPM: ambulatory blood pressure monitoring; AML: amlodipine) The primary end point of the study is the change in arterial blood pressure after 12 weeks of treatment compared to baseline at 24 hours.
Simultaneous study The safety of drug use was also evaluated.
Figure 2: A.
Comparison of baseline and 12-week average 24-hour dynamic blood systolic blood pressure per hour; B.
Baseline and 12-week average 24-hour dynamic blood diastolic blood pressure comparison between baseline and sitting blood pressure of 158.
8±13.
1/89.
1±10.
1mmHg , The average 24-hour ambulatory blood pressure is 144.
4±11.
7/81.
6±9.
8mmHg.
After 12 weeks of intervention, the average 24-hour ambulatory blood pressure of the population decreased by -19.
9±0.
8/-11.
2±0.
5mmHg (p <0.
0001), and the 24-hour ambulatory blood pressure of 70% of patients reached the standard (<130/80mmHg).
In addition, for subjects whose blood pressure was not up to standard at 12 weeks and hydrochlorothiazide treatment, the average 24-hour ambulatory blood pressure drop after 18 weeks of treatment decreased by 28.
0±1.
5/13.
7±1.
0 mmHg (p <0.
0001) compared with baseline.
Among them, 62% of patients reached the recommended sitting blood pressure target (<130/80mmHg).
In terms of safety, 19.
3% of patients had adverse reactions caused by drugs.
The most common adverse events were peripheral edema, dizziness and hypotension.
In the superimposed hydrochlorothiazide group, the incidence of dizziness and hypotension was slightly higher than that in the non-combined application group, but no metabolic-related side effects caused by the drug were seen.
This study shows that the antihypertensive regimen of amlodipine + olmesartan medoxomil with or without hydrochlorothiazide is well tolerated for patients with type 2 diabetes and hypertension, and can achieve stable blood pressure control within 24 hours and reduce early morning hypertension.
Potential cardiovascular risk.
In 2005, the American Heart Association believed that the normal 24-hour blood pressure, day blood pressure and night blood pressure should be <130/80mmHg, <135/85mmHg and 120/70mmHg.
In this trial, 70% of subjects can be treated with amlodipine + olmesartan medoxomil to control the 24-hour blood pressure at <130/80mmHg.
TIME interactive time is convenient to use and has few side effects.
Olmesartan medoxomil and amlodipine are suitable for hypertensive patients of all ages.
Lin Wei, deputy chief physician of the Department of Cardiology, Beijing Boai Hospital.
Can not be fixed.
Therefore, for young hypertensive patients who have used single-agent blood pressure control that does not meet the standard, the single-tablet compound preparation olmesartan medoxomil and amlodipine can control blood pressure more effectively and stably.
Single-tablet compound preparations are simple to use.
Only one tablet a day is needed to keep the patient's blood pressure up to standard and improve the prognosis of hypertension.
In addition, the elderly are likely to have orthostatic hypotension and high blood pressure fluctuations.
I will also give priority to it.
Olmesartan medoxomil and amlodipine help blood pressure reach the target, improve the damage of target organs of hypertension, the incidence of hypotension is low, and it has significant advantages in clinical application.
Clinical experience shows that olmesartan medoxomil and amlodipine have better antihypertensive effects than other types of compound preparations Chen Wei, chief physician of the Department of Cardiology, Qingdao Central Hospital, 2020 European Society of Hypertension/European Society of Cardiology (ESH/ESC) Hypertension Management Guidelines clearly point out : Most hypertensive patients should start to use combination therapy to increase the rate of compliance.
Angiotensin receptor antagonist (ARB)/CCB combination, especially single-tablet compound preparation, is the preferred initial combination therapy for most hypertensive patients.
ARB olmesartan medoxomil, as the latest generation of ARB drugs, has a more potent, long-lasting and stable antihypertensive effect due to its unique "2046" structure.
Its combination with CCB amlodipine is a powerful antihypertensive treatment The model of strong combination is a clinically preferred treatment plan that can achieve strong blood pressure reduction, high compliance rate and good tolerability.
Olmesartan and amlodipine reduce the incidence of peripheral edema and improve patient compliance, especially in reducing central arterial pressure, which is significantly better than other combinations.
It is the preferred solution for patients with hypertension.
As one of the first national hypertension standard centers, our department has accumulated considerable experience in the use of olmesartan medoxomil and amlodipine tablets.
For patients whose single drug does not meet the standard, or the combination of two or more single drugs does not meet the standard, or the use of other compound preparations still does not meet the standard, it is recommended to use olmesartan medoxomil and amlodipine tablets, which have achieved ideal blood pressure lowering effects.
It is especially suitable for the elderly who take more drugs in combination.
ARB has been applied but the effect of lowering blood pressure is not good, consider switching to Olmesartan medoxomil Liang Yuqing, Deputy Chief Physician of Department of Cardiology, Beijing Chuiyangliu Hospital, Olmesartan Amlodipine Tablets have proven their potent antihypertensive effect, whether it is simple or high Blood pressure patients, or special populations (such as hypertension patients with diabetes, hypertension patients with obesity, elderly hypertension patients, etc.
) Olmesartan medoxomil and amlodipine have good blood pressure lowering effects, and its blood pressure reduction range can be based on the patient's blood pressure Changes in the baseline level can better reduce the occurrence of adverse reactions.
In clinical work, for patients who have already used ARB but still have poor blood pressure control, I will choose to switch to olmesartan medoxomil and amlodipine to help patients achieve their target blood pressure.
Clinical application experience sharing Teng Jiwei, deputy chief physician of the Department of Cardiology, the Second Affiliated Hospital of the PLA Air Force Military Medical University, reduces blood pressure all day long, and olmesartan medoxomil and amlodipine improve patient compliance.
The compound combination preparation for the treatment of hypertension has been increasing.
The more such drugs can reduce the frequency of medication and help improve patient compliance with medication.
Olmesartan medoxomil and amlodipine can reduce blood pressure throughout the day for a long time.
The incidence of adverse events is as low as 2%, and the occurrence of edema is significantly lower than that of amlodipine alone.
Therefore, the application of the drug can significantly improve the quality of life of patients and improve patient compliance.
For patients with acute coronary syndrome and heart failure, the application of ARB can improve the patient's ventricular remodeling and improve the patient's heart function.
Dai Jinjie, Deputy Chief Physician of the Department of Cardiology, Shanghai Jiao Tong University Chest Hospital, is mature in single-drug applications, and combined with more significant effects.
Combining drugs is a trend in the treatment of hypertension.
ARB and CCB are both mature drug types that have accumulated many years of experience in drug use.
The combination of serotonin helps to reduce blood pressure and reduce the occurrence of side effects.
Olmesartan medoxomil and amlodipine can make 85% of Chinese hypertensive patients reach the standard without increasing the incidence of hypotension.
The patients have good tolerance and compliance, so the antihypertensive effect is worth looking forward to.
Wang Yunman, Deputy Chief Physician of the Department of Nephrology, Shanghai Putuo District Central Hospital, blood pressure reduction + kidney protection should be the dual standard of antihypertensive medication for patients with CKD.
For CKD patients, the survival benefit of pure blood pressure control is dependent on the patient’s nephropathy.
Progress and weakening.
Taking urinary protein as the treatment target can effectively inhibit the progression of kidney disease and protect renal function.
ARB can reduce blood pressure while reducing urinary protein to protect kidney function.
Olmesartan medoxomil and amlodipine have sufficient evidence-based medical support, which is in line with the latest European guidelines for hypertension and the Chinese guidelines for single-tablet compound preparation recommendations.
We believe that blood pressure control and renal function protection require the combination of ARB and CCB.
Their strong combination can truly increase the rate of patient blood pressure compliance and improve patient compliance.
Scan the QR code below to get more cardiovascular knowledge.
